1.Moradi Tuchayi S, Makrantonaki E, Ganceviciene R, Dessinioti C, Feldman SR, Zouboulis CC. Acne vulgaris Nat Rev Dis Primers. 2015;1:15029.

2.Goodman GJ, Baron JA. Postacne scarring–a quantitative global scarring grading system. J Cosmet Dermatol. 2006;5:48–52.

3.Ogawa R. Japan Scar Workshop (JSW) Scar Scale (JSS) for Assessing Keloids and Hypertrophic Scars. In: Téot L, Mustoe TA, Middelkoop E, Gauglitz GG (eds). Textbook on Scar Management: State of the Art Management and Emerging Technologies [Internet]. Cham (CH): Springer; 2020. Chapter 15.

4.Clark AK, Saric S, Sivamani RK. Acne scars: how do we grade them? Am J Clin Dermatol. 2018;19:139–44.

5.Layton AM, Henderson CA, Cunliffe WJ. A clinical evaluation of acne scarring and its incidence. Clinical & Experimental Dermatology. 1994;19:303–8.

6.Gold MH, Nestor MS, Berman B, Goldberg D. Assessing keloid recurrence following surgical excision and radiation. Burns. Trauma. 2020;8:tkaa031.

7.Lee YJ, Lee CY, Shin MK. A neglected acne scar type: Papular acne scars and their correlations with keloid scars. Dermatol Surg. 2021;47:1347–51.

8.Hayashi N, Miyachi Y, Kawashima M. Prevalence of scars and ``mini-scars'', and their impact on quality of life in Japanese patients with acne. J Dermatol. 2015;42:690–6.

9.Tan J, Kang S, Leyden J. Prevalence and risk factors of acne scarring among patients consulting dermatologists in the USA. J Drugs Dermatol. 2017;16:97–102.

10.Tan JK, Bhate K. A global perspective on the epidemiology of acne. Br J Dermatol. 2015;172:3–12.

11.Ogawa R, Akaishi S. Endothelial dysfunction may play a key role in keloid and hypertrophic scar pathogenesis–keloids and hypertrophic scars may be vascular disorders. Med Hypotheses. 2016;96:51–60.

12.Andrews JP, Marttala J, Macarak E, Rosenbloom J, Uitto J. Keloids: the paradigm of skin fibrosis - Pathomechanisms and treatment. Matrix Biol. 2016;51:37–46.

13.Cohen AJ, Nikbakht N, Uitto J. Keloid disorder: genetic basis, gene expression profiles, and immunological modulation of the fibrotic processes in the skin. Csh Perspect Biol. 2023;15:a041245.

14.Doolan BJ, Onoufriadis A, Kantaputra P, McGrath JA. WNT10A, dermatology and dentistry. Brit J Dermatol. 2021;185:1105–11.

15.Gupta N, Bishnoi A, Mathew D, Arora A, Handa S, Kaur J, et al.  Hypertrophic post-acne scarring is associated with a single nucleotide polymorphism (rs243865) in the matrix metalloproteinase-2 gene. Journal Der Deutschen Dermatologischen Gesellschaft. 2020;18:1426–35.

16.Degitz K, Placzek M, Borelli C, Plewig G. Pathophysiology of acne. J Dtsch Dermatol Ges. 2007;5:316–23.

17.Jiao H, Zhang T, Fan J, Xiao R. The superficial dermis may initiate keloid formation: histological analysis of the keloid dermis at different depths. Front Physiol. 2017;8:885.

18.van der Veer WM, Bloemen MC, Ulrich MM, Molema G, van Zuijlen PP, Middelkoop E, et al.  Potential cellular and molecular causes of hypertrophic scar formation. Burns. 2009;35:15–29.

19.Kurokawa I, Layton AM, Ogawa R. Updated treatment for acne: targeted therapy based on pathogenesis. Dermatol Ther (Heidelb). 2021;11:1129–39.

20.Grice EA, Kong HH, Conlan S, Deming CB, Davis J, Young AC, et al.  Topographical and temporal diversity of the human skin microbiome. Science. 2009;324:1190–2.

21.Oh J, Byrd AL, Park M, Program NCS, Kong HH, Segre JA. Temporal stability of the human skin microbiome. Cell. 2016;165:854–66.

22.Jahns AC, Lundskog B, Ganceviciene R, Palmer RH, Golovleva I, Zouboulis CC, et al.  An increased incidence of Propionibacterium acnes biofilms in acne vulgaris: a case-control study. Br J Dermatol. 2012;167:50–8.

23.Kurokawa I, Danby FW, Ju Q, Wang X, Xiang LF, Xia L, et al.  New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol. 2009;18:821–32.

24.Sugisaki H, Yamanaka K, Kakeda M, Kitagawa H, Tanaka K, Watanabe K, et al.  Increased interferon-gamma, interleukin-12p40 and IL-8 production in Propionibacterium acnes-treated peripheral blood mononuclear cells from patient with acne vulgaris: host response but not bacterial species is the determinant factor of the disease. J Dermatol Sci. 2009;55:47–52.

25.Dreno B, Bagatin E, Blume-Peytavi U, Rocha M, Gollnick H. Female type of adult acne: physiological and psychological considerations and management. J Dtsch Dermatol Ges. 2018;16:1185–94.

26.Canesso MC, Vieira AT, Castro TB, Schirmer BG, Cisalpino D, Martins FS, et al.  Skin wound healing is accelerated and scarless in the absence of commensal microbiota. J Immunol. 2014;193:5171–80.

27.Chen WJ, Dijke PT. Immunoregulation by members of the TGFβ superfamily. Nat Rev Immunol. 2016;16:723–40.

28.Morry J, Ngamcherdtrakul W, Yantasee W. Oxidative stress in cancer and fibrosis: opportunity for therapeutic intervention with antioxidant compounds, enzymes, and nanoparticles. Redox Biol. 2017;11:240–53.

29.Kelhala HL, Palatsi R, Fyhrquist N, Lehtimaki S, Vayrynen JP, Kallioinen M, et al.  IL-17/Th17 pathway is activated in acne lesions. PLoS One. 2014;9:e105238.

30.Agak GW, Qin M, Nobe J, Kim MH, Krutzik SR, Tristan GR, et al.  Propionibacterium acnes induces an IL-17 response in acne vulgaris that is regulated by vitamin a and vitamin D. J Invest Dermatol. 2014;134:366–73.

31.Mohr A, Malhotra R, Mayer G, Gorochov G, Miyara M. Human FOXP3(+) T regulatory cell heterogeneity. Clin Transl Immunology. 2018;7:e1005.

32.Dahmani A, Delisle JS. TGF-beta in T cell biology: implications for cancer immunotherapy. Cancers (Basel). 2018;10:194.

33.Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-β: the master regulator of fibrosis. Nat Rev Nephrol. 2016;12:325–38.

34.Ud-Din S, Wilgus TA, Bayat A. Mast cells in skin scarring: a review of animal and human research. Front Immunol. 2020;11:552205.

35.Shi J, Wang H, Guan H, Shi S, Li Y, Wu X, et al.  IL10 inhibits starvation-induced autophagy in hypertrophic scar fibroblasts via cross talk between the IL10-IL10R-STAT3 and IL10-AKT-mTOR pathways. Cell Death Dis. 2016;7:e2133.

36.Kieran I, Knock A, Bush J, So K, Metcalfe A, Hobson R, et al.  Interleukin reduces scar formation in both animal and human cutaneous wounds: results of two preclinical and phase II randomized control studies. Wound Repair Regen. 2013;21:428–36.

37.Marshall CD, Hu MS, Leavitt T, Barnes LA, Longaker MT. Cutaneous scarring: basic science, current treatments, and future directions. Advances in Wound Care. 2016;7:29.

38.Cong TX, Hao D, Wen X, Li XH, He G, Jiang X. From pathogenesis of acne vulgaris to anti-acne agents. Arch Dermatol Res. 2019;311:337–49.

39.Ben-Amitai D, Laron Z. Effect of insulin-like growth factor-1 deficiency or administration on the occurrence of acne. J Eur Acad Dermatol Venereol. 2011;25:950–4.

40.Hu ZC, Tang B, Guo D, Zhang J, Liang YY, Ma D, et al.  Expression of insulin-like growth factor-1 receptor in keloid and hypertrophic scar. Clin Exp Dermatol. 2014;39:822–8.

41.Seo GY, Lim Y, Koh D, Huh JS, Hyun C, Kim YM, et al.  TMF and glycitin act synergistically on keratinocytes and fibroblasts to promote wound healing and anti-scarring activity. Exp Mol Med. 2017;49:e302.

42.Wang Q, Cai J, Fang C, Yang C, Zhou J, Tan Y, et al.  Mesenchymal glioblastoma constitutes a major ceRNA signature in the TGF-beta pathway. Theranostics. 2018;8:4733–49.

43.Zouboulis CC, Bettoli V. Management of severe acne. Br J Dermatol. 2015;172:27–36.

44.Kiritsi D, Nystrom A. The role of TGFbeta in wound healing pathologies. Mech Ageing Dev. 2018;172:51–8.

45.McNairn AJ, Doucet Y, Demaude J, Brusadelli M, Gordon CB, Uribe-Rivera A, et al.  TGFbeta signaling regulates lipogenesis in human sebaceous glands cells. BMC Dermatol. 2013;13:2.

46.Kruglikov IL, Scherer PE. Caveolin-1 as a possible target in the treatment for acne. Exp Dermatol. 2020;29:177–83.

47.Ji X, Wang H, Wu Z, Zhong X, Zhu M, Zhang Y, et al.  Specific inhibitor of Smad3 (SIS3) attenuates fibrosis, apoptosis, and inflammation in unilateral ureteral obstruction kidneys by inhibition of transforming growth factor beta (TGF-beta)/Smad3 Signaling. Med Sci Monit. 2018;24:1633–41.

48.He S, Liu X, Yang Y, Huang W, Xu S, Yang S, et al.  Mechanisms of transforming growth factor beta(1)/Smad signalling mediated by mitogen-activated protein kinase pathways in keloid fibroblasts. Brit J Dermatol. 2010;162:538–46.

49.Yu Y, Shen YJ, Zhang SY, Wang N, Luo L, Zhu XY, et al.  Suppression of Cutibacterium acnes-mediated inflammatory reactions by fibroblast growth factor 21 in skin. Int J Mol Sci. 2022;23:3589.

50.Zhou BY, Wang WB, Wu XL, Zhang WJ, Zhou GD, Gao Z, et al.  Nintedanib inhibits keloid fibroblast functions by blocking the phosphorylation of multiple kinases and enhancing receptor internalization. Acta Pharmacol Sin. 2020;41:1234–45.

51.Wilgus TA, Ferreira AM, Oberyszyn TM, Bergdall VK, Dipietro LA. Regulation of scar formation by vascular endothelial growth factor. Lab Investig. 2008;88:579–90.

52.Wu WS, Wang FS, Yang KD, Huang CC, Kuo YR. Dexamethasone induction of keloid regression through effective suppression of VEGF expression and keloid fibroblast proliferation. J Invest Dermatol. 2006;126:1264–71.

53.Chen J, Zhao S, Liu Y, Cen Y, Nicolas C. Effect of captopril on collagen metabolisms in keloid fibroblast cells. ANZ J Surg. 2016;86:1046–51.

54.Habeshian KA, Cohen BA. Current issues in the treatment of acne vulgaris. Pediatrics. 2020;145:S225–30.

55.Mysore V, Omprakash HM, Khatri GN. Isotretinoin and dermatosurgical procedures. Indian J Dermatol Venereol Leprol. 2019;85:18–23.

56.Kim HW, Chang SE, Kim JE, Ko JY, Ro YS. The safe delivery of fractional ablative carbon dioxide laser treatment for acne scars in Asian patients receiving oral isotretinoin. Dermatol Surg. 2014;40:1361–6.

57.Dréno B, Layton A, Zouboulis CC, López-Estebaranz JL, Zalewska-Janowska A, Bagatin E, et al.  Adult female acne: a new paradigm. J Eur Acad Dermatol Venereol. 2013;27:1063–70.

58.Demir CY, Ersoz ME, Erten R, Kocak OF, Sultanoglu Y, Basbugan Y. Comparison of Enalapril, candesartan and Intralesional triamcinolone in reducing hypertrophic scar development: an experimental study. Aesthet Plast Surg. 2018;42:352–61.

59.Fung MA, Berger TG. A prospective study of acute-onset steroid acne associated with administration of intravenous corticosteroids. Dermatology. 2000;200:43–4.

60.Shibata M, Katsuyama M, Onodera T, Ehama R, Hosoi J, Tagami H. Glucocorticoids enhance toll-like receptor 2 expression in human keratinocytes stimulated with Propionibacterium acnes or proinflammatory cytokines. J Invest Dermatol. 2009;129:375–82.

61.Austin E, Koo E, Jagdeo J. The cellular response of keloids and hypertrophic scars to botulinum toxin a: a comprehensive literature review. Dermatol Surg. 2018;44:149–57.

62.Kim SH, Lee SJ, Lee JW, Jeong HS, Suh IS. Clinical trial to evaluate the efficacy of botulinum toxin type a injection for reducing scars in patients with forehead laceration: a double-blinded, randomized controlled study. Medicine (Baltimore). 2019;98:e16952.

63.Zhang DZ, Liu XY, Xiao WL, Xu YX. Botulinum toxin type a and the prevention of hypertrophic scars on the maxillofacial area and neck: a meta-analysis of randomized controlled trials. PLoS One. 2016;11:e0151627.

64.Hong SZ, Zhang JJ, Hong F. Long-term effect of botulinum toxin type a injection on hypertrophic acne scar. Zhonghua Zheng Xing Wai Ke Za Zhi. 2016;32:432–7.

65.Shaarawy E, Hegazy RA, Abdel HRM. Intralesional botulinum toxin type a equally effective and better tolerated than intralesional steroid in the treatment of keloids: a randomized controlled trial. J Cosmet Dermatol. 2015;14:161–6.

66.Trisliana Perdanasari A, Torresetti M, Grassetti L, Nicoli F, Zhang YX, Dashti T, et al.  Intralesional injection treatment of hypertrophic scars and keloids: a systematic review regarding outcomes. Burns Trauma. 2015;3:14.

67.Li Y, Shan X, Mao Q, Xiang R, Cai Z. Botulinum toxin type a intralesional monotherapy for treating human hypertrophic scar in a dose-dependent manner: in an animal model. J Plast Reconstr Aesthet Surg. 2021;74:3186–95.

68.Zhang SN, Peng Y, Fan H, Zhang YX, Min PR. Microneedle delivery of botulinum toxin type a combined with hyaluronic acid for the synergetic management of multiple sternal keloids with oily skin: a retrospective clinical investigation. J Cosmet Dermatol. 2022;21:5601–9.

69.Liu YLZ, Hu J, Zhan S, Wang M, Wang L. Treatment of acne by subcutaneous injection of low-concentration 5-fluorouracil. J Cosmet Dermatol. 2021;00:1–2.

70.In Ryu S, Suh DH, Lee SJ, Kim KE, Jeong JY, Ryu HJ. Efficacy and safety of intense pulsed light using a dual-band filter for the treatment of facial acne vulgaris. Lasers Med Sci. 2022;37:531–6.

71.Barakat MT, Moftah NH, El Khayyat MA, Abdelhakim ZA. Significant reduction of inflammation and sebaceous glands size in acne vulgaris lesions after intense pulsed light treatment. Dermatol Ther. 2017;30:e12418.

72.Li MK, Liu C, Hsu JTS. The use of lasers and light devices in acne management: an update. Am J Clin Dermatol. 2021;22:785–800.

73.Kawana S, Tachihara R, Kato T, Omi T. Effect of smooth pulsed light at 400 to 700 and 870 to 1,200 nm for acne vulgaris in Asian skin. Dermatol Surg. 2010;36:52–7.

74.Piccolo D, Kostaki D, Dianzani C, Crisman G, Conforti C. Effective intense pulsed light protocol in the treatment of moderate to severe acne vulgaris of the chest and back. J Clin Aesthet Dermatol. 2022;15:22–5.

75.Yuan B, Upton Z, Leavesley D, Fan C, Wang XQ. Vascular and collagen target: a rational approach to hypertrophic scar management. Adv Wound Care (New Rochelle). 2023;12:38–55.

76.Liu XJ, Liu WH, Fang SW, Zhou XL, Xu JX, Li GS. Lasers and intense pulsed light for the treatment of pathological scars: a network meta-analysis. Aesthet Surg J. 2022;42:NP675–87.

77.Jeong E, Hong JW, Min JA, Lee DW, Sohn MY, Lee WJ, et al.  Topical ALA-photodynamic therapy for acne can induce apoptosis of Sebocytes and down-regulate their TLR-2 and TLR-4 expression. Ann Dermatol. 2011;23:23–32.

78.Nicklas C, Rubio R, Cardenas C, Hasson A. Comparison of efficacy of aminolaevulinic acid photodynamic therapy vs. adapalene gel plus oral doxycycline for treatment of moderate acne vulgaris-a simple, blind, randomized, and controlled trial. Photodermatol Photoimmunol Photomed. 2019;35:3–10.

79.Yang L, Deng H, Chen Y, Chen Y, Guo L, Feng M. 5-Aminolevulinic acid-hyaluronic acid complexes enhance skin retention of 5-Aminolevulinic acid and therapeutic efficacy in the treatment of hypertrophic scar. AAPS PharmSciTech. 2022;23:216.

80.Huang Y, Peng T, Hu W, Gao X, Chen Y, Zhang Q, et al.  Fully armed photodynamic therapy with spear and shear for topical deep hypertrophic scar treatment. J Control Release. 2022;343:408–19.

81.Leheta TM. Role of the 585-nm pulsed dye laser in the treatment of acne in comparison with other topical therapeutic modalities. J Cosmet Laser Ther. 2009;11:118–24.

82.Keaney TC, Tanzi E, Alster T. Comparison of 532 nm potassium Titanyl phosphate laser and 595 nm pulsed dye laser in the treatment of erythematous surgical scars: a randomized, controlled. Open-Label Study Dermatol Surg. 2016;42:70–6.

83.Khatri KA, Mahoney DL, McCartney MJ. Laser scar revision: a review. J Cosmet Laser Ther. 2011;13:54–62.

84.Nouri K, Rivas MP, Stevens M, Ballard CJ, Singer L, Ma F, et al.  Comparison of the effectiveness of the pulsed dye laser 585 nm versus 595 nm in the treatment of new surgical scars. Lasers Med Sci. 2009;24:801–10.

85.Deng H, Tan T, Luo G, Tan J, Li-Tsang CWP. Vascularity and thickness changes in immature hypertrophic scars treated with a pulsed dye laser. Lasers Surg Med. 2020;53:914–21.

86.Donelan MB, Parrett BM, Sheridan RL. Pulsed dye laser therapy and z-plasty for facial burn scars: the alternative to excision. Ann Plast Surg. 2008;60:480–6.

87.Tredget EE, Levi B, Donelan MB. Biology and principles of scar management and burn reconstruction. Surg Clin North Am. 2014;94:793–815.

88.Paquet P, Hermanns JF, Pierard GE. Effect of the 585 nm flashlamp-pumped pulsed dye laser for the treatment of keloids. Dermatol Surg. 2001;27:171–4.

89.Yang Q, Ma Y, Zhu R, Huang G, Guan M, Avram MM, et al.  The effect of flashlamp pulsed dye laser on the expression of connective tissue growth factor in keloids. Lasers Surg Med. 2012;44:377–83.

90.Kuo YR, Wu WS, Jeng SF, Wang FS, Huang HC, Lin CZ, et al.  Suppressed TGF-beta1 expression is correlated with up-regulation of matrix metalloproteinase-13 in keloid regression after flashlamp pulsed-dye laser treatment. Lasers Surg Med. 2005;36:38–42.

91.Hantash BM, Bedi VP, Chan KF, Zachary CB. Ex vivo histological characterization of a novel ablative fractional resurfacing device. Lasers Surg Med. 2007;39:87–95.

92.Shin JU, Lee SH, Jung JY, Lee JH. A split-face comparison of a fractional microneedle radiofrequency device and fractional carbon dioxide laser therapy in acne patients. J Cosmet Laser Ther. 2012;14:212–7.

93.Sorkin M, Cholok D, Levi B. Scar Management of the Burned Hand. Hand Clin. 2017;33:305–15.

94.Azzam OA, Bassiouny DA, El-Hawary MS, El Maadawi ZM, Sobhi RM, El-Mesidy MS. Treatment of hypertrophic scars and keloids by fractional carbon dioxide laser: a clinical, histological, and immunohistochemical study. Lasers Med Sci. 2016;31:9–18.

95.Srivastava S, Kumari H, Singh A. Comparison of fractional CO(2) laser, verapamil, and triamcinolone for the treatment of keloid. Adv Wound Care (New Rochelle). 2019;8:7–13.

96.Ozog DM, Liu A, Chaffins ML, Ormsby AH, Fincher EF, Chipps LK, et al.  Evaluation of clinical results, histological architecture, and collagen expression following treatment of mature burn scars with a fractional carbon dioxide laser. JAMA Dermatol. 2013;149:50–7.

97.Miletta N, Siwy K, Hivnor C, Clark J, Shofner J, Zurakowski D, et al.  Fractional ablative laser therapy is an effective treatment for hypertrophic burn scars: a prospective study of objective and subjective outcomes. Ann Surg. 2021;274:e574–80.

98.Elgarhy LH, El-Tatawy RA, Abdelaziz D, Dogheim NN. Pulsed dye laser versus ablative fractional CO(2) laser in treatment of old hypertrophic scars: Clinicopathological study. Wound Repair Regen. 2021;29:417–24.

99.Arima J, Dohi T, Kuribayashi S, Akaishi S, Ogawa R. Z-plasty and postoperative radiotherapy for anterior Chest Wall keloids: an analysis of 141 patients. Prs-Glob Open. 2019;7:e2177.

100.Mustoe TA, Cooter RD, Gold MH, Hobbs R, Ramelet AA, Shakespeare PG, et al.  International clinical recommendations on scar management. Plast Reconstr Surg. 2002;110:560–71.

101.Ogawa R. The most current algorithms for the treatment and prevention of hypertrophic scars and keloids: a 2020 update of the algorithms published 10 years ago. Plast Reconstr Surg. 2022;149:79e–4.

102.Mankowski P, Kanevsky J, Tomlinson J, Dyachenko A, Luc M. Optimizing radiotherapy for keloids a meta-analysis systematic review comparing recurrence rates between different radiation modalities. Ann Plas Surg. 2017;78:403–11.

103.Huang CY, Liu LW, You ZF, Du YA, Ogawa R. Managing keloid scars: from radiation therapy to actual and potential drug deliveries. Int Wound J. 2019;16:852–9.

104.Shirakami E, Yamakawa S, Hayashida K. Strategies to prevent hypertrophic scar formation: a review of therapeutic interventions based on molecular evidence. Burns & Trauma. 2020;8:tkz003.

105.Ai JWLJ, Pei SD, Liu Y, Li DS, Lin HM, Pei B. The effectiveness of pressure therapy (15-25 mmHg) for hypertrophic burn scars: a systematic review and meta-analysis. Sci Rep. 2017;7:40185.